The impact of diabetic retinopathy on health-related quality of life

Current Opinion in Ophthalmology

Volumn 16, Issue 3, 2005, Pages 155-159

  Sharma, Sanjay ^a,c   Oliver Fernandez, Alejandro ^a   Liu, Wei ^a   Buchholz, Patricia ^b   Walt, John ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b ALLERGAN INC   (United States)

^c HOTEL DIEU HOSPITAL   (Canada)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Health related quality of life; Intervention; Laser photocoagulation

Indexed keywords

ANGIOGRAPHY; DIABETES MELLITUS; DIABETIC RETINOPATHY; HEALTH SURVEY; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RETINOPATHY; RETINOPATHY DEPENDENT QUALITY OF LIFE QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FUNCTION INDEX; VISUAL FUNCTION QUESTIONNAIRE;

DIABETIC RETINOPATHY; HEALTH STATUS INDICATORS; HUMANS; LASER COAGULATION; MACULAR EDEMA, CYSTOID; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 18844433338     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000161227.21797.3d     Document Type: Review

References (22)

1. Kempen JH, O'Colmain BJ, Leske MC, et al., Eye Disease Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122:552-556. In this study, pooled data from eight population-based studies demonstrated that among an estimated 10.2 million adults 40 years or older known to have diabetes mellitus in the United States, the estimated crude prevalence rates for retinopathy and vision-threatening retinopathy were 40.3% and 8.2%, respectively.
2. Roy MS, Klein R, O'Colmain BJ, et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 2004; 122:546-551.
3. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologie Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105:1801-1815.
4. Klein R, Moss SE, Klein BE, et al. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2001; 119:733-740.
5. Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998; 42:17-27.
6. Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia 2002; 45:1617-1634.
7. Brandle M, Davidson MB, Schriger DL, et al. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003; 26:2300-2304.
8. Smith AF. The economic impact of ophthalmic services for persons with diabetes in the Canadian province of Nova Scotia: 1993-1996. Ophthalmic Epidemiol 2001; 8:13-25.
9. Klein BE, Klein R, Moss SE. Self-related health and diabetes of long duration. The Wisconsin Epidemiology Study of Diabetic Retinopathy. Diabetes Care 1998; 21:236-240.
10. Linder M, Chang TS, Scott IU, et al. Validity of the visual function index (VF-14) in patients with retinal disease. Arch Ophthalmol 1999; 117:1611-1616.
11. Woodcock A, Bradley C, Plowright R, et al. The influence of diabetic retinopathy on quality of life: interviews to guide the design of a condition-specific, individualized questionnaire: the Ret D QoL. Patient Educ Couns 2004; 53:365-383.
12. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol 1994; 112:630-638.
13. Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol 1998; 116:1496-1504.
14. Torrance GW. Utility approach to measuring health related quality of life. J Chronic Dis 1987; 40:593-603.
15. Von Neumann J, Morgenstern O. Theory of games and economic behavior. Princeton, New Jersey: Princeton University Press, 1944.
16. Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002; 120:481-484.
17. Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol 2003; 87:259-261.
18. Shah VA, Gupta SK, Shah KV, et al. TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiol 2004; 11:43-51.
19. Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000; 35:127-133.
20. Riusala A, Sarna A, Immonen I. Visual function index (VF-14) in exudative age-related macular degeneration. Am J Ophthalmol 2003; 135:206-212.
21. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94:761-774.
22. Tranos PG, Topouzis F, Stangos NT, et al. Effect of laser photocoagulation treatment for diabetic macular oedema on patient's vision-related quality of life. Curr Eye Res 2004; 29:41-49.